Authors: BOWEN DT GELLY K HEPBURN M KANZ L BRUGGER W DENZLINGER C CULLIGAN D

Citation: Dt. Bowen et al., LOW RESPONSE RATE TO A CONTINUOUS SCHEDULE OF AMIFOSTINE FOR LOW-RISKMYELODYSPLASTIC PATIENTS, British Journal of Haematology, 102(1), 1998, pp. 344-344

Authors: GRIMWADE D GORMAN P DUPREZ E HOWE K LANGABEER S OLIVER F WALKER H CULLIGAN D WATERS J POMFRET M GOLDSTONE A BURNETT A FREEMONT P SHEER D SOLOMON E

Citation: D. Grimwade et al., CHARACTERIZATION OF CRYPTIC REARRANGEMENTS AND VARIANT TRANSLOCATIONSIN ACUTE PROMYELOCYTIC LEUKEMIA, Blood, 90(12), 1997, pp. 4876-4885

Authors: LIM SH CULLIGAN D COUZENS S FISHER J JOHN S POLLARD P BURNETT A WHITTAKER J

Citation: Sh. Lim et al., MOLECULAR EVIDENCE FOR A COMMON LEUKEMIC PROGENITOR IN ACUTE MIXED LYMPHOID AND MYELOID-LEUKEMIA, British Journal of Haematology, 92(1), 1996, pp. 131-133

Authors: BOWEN DT CULLIGAN D BEGUIN Y KENDALL R WILLIS N

Citation: Dt. Bowen et al., ESTIMATION OF EFFECTIVE AND TOTAL ERYTHROPOIESIS IN MYELODYSPLASIA USING SERUM TRANSFERRIN RECEPTOR AND ERYTHROPOIETIN CONCENTRATIONS, WITHAUTOMATED RETICULOCYTE PARAMETERS, Leukemia, 8(1), 1994, pp. 151-155

Authors: TENNANT GB ALSABAH AI CULLIGAN D BOWEN DT JACOBS A BURNETT AK

Citation: Gb. Tennant et al., IN-VITRO RESPONSE OF MYELOID PROGENITORS TO PHYTOHAEMAGGLUTIN AND INTERLEUKIN-2 IS RELATED TO SURVIVAL OF SOME MYELODYSPLASTIC PATIENTS, Experimental hematology, 21(8), 1993, pp. 1036-1036

Authors: BOWEN D YANCIK S BENNETT L CULLIGAN D RESSER K

Citation: D. Bowen et al., SERUM STEM-CELL FACTOR CONCENTRATION IN PATIENTS WITH MYELODYSPLASTICSYNDROMES, British Journal of Haematology, 85(1), 1993, pp. 63-66